Stay current with the latest news on Blood Cancer United research programs, FDA approvals, research grants and awards, the Therapy Acceleration Program, Beat AML and other clinical research programs, and more.
News
FDA Approves a Patient-Friendly, Dissolvable Therapeutic for Chronic Myeloid Leukemia
The dissolvable format may also benefit individuals who have difficulty swallowing pills, offering greater flexibility and ease of use.
News
FDA Approves New Treatment for an Ultra‑Rare, Aggressive Blood Cancer
“This is meaningful for patients with BPDCN, where choices have historically been limited, especially for those whose disease has relapsed or stopped …
News
Blood Cancer United Data at 2026 ASCO and EHA Highlight Beat AML Progress, Patient Experience Insights and Access Barriers
Blood Cancer United-funded researchers will present findings spanning novel treatment approaches and optimization strategies, real-world access and co…
News
Blood Cancer United’s Therapy Acceleration Program Receives $1M Grant from Blood Cancer UK
Blood Cancer United is actively growing TAP to increase its portfolio and become self-sustaining while continuing to advance the organization's missio…
News
FDA Approves Oral Combo Treatment for Older Adults with Newly Diagnosed AML
“Older adults make up the majority of people diagnosed with AML, and unfortunately many are not eligible for or cannot tolerate intensive chemotherapy…
News
Blood Cancer United Receives AWS Grant to Expand Use of Generative AI in Beat AML Master Clinical Trial Tool
Grant will scale AI‑driven automation for regulatory documentation to help accelerate clinical research.
News
FDA Expands Approval of Chemoimmunotherapy Combination for People with Classical Hodgkin Lymphoma
Research funded by Blood Cancer United helped establish the importance of the PD‑1 pathway in classical Hodgkin lymphoma—a foundational insight that l…
News
FDA Approves Combination Treatment for Multiple Myeloma
Blood Cancer United has played a long-term role in supporting the foundational research that paved the way for this approval. Over more than a decade,…
News
FDA OKs the First All-Oral, Time‑Limited Treatment Option for Adults Newly Diagnosed with Most Common Form of Leukemia
A major focus of Blood Cancer United's work is supporting time‑limited treatments like this new acalabrutinib approval that are effective but do not r…
News
FDA Expands CAR T Approval to Include Patients with Rare, Aggressive Type of Non-Hodgkin Lymphoma
Blood Cancer United provided funding for the clinical trial that led to the original approval of axi-cel through its Therapy Acceleration Program® and…
News
FDA Approves Combination Therapy for Newly Diagnosed Multiple Myeloma
“This approval represents an important step forward for people who are newly diagnosed with this disease,” said Lore Gruenbaum, Ph.D., Chief Scientifi…
News
Blood Cancer United Expands its Beat AML® Master Clinical Trial Advancing Next-Generation Treatment
In collaboration with AVEO Oncology, an LG Chem company, (“AVEO”) the new Beat AML sub-study is evaluating ficlatuzumab, a monoclonal antibody targeti…
